Under the liquidity contract entrusted by the company THERANEXUS to PORTZAMPARC, GROUPE BNP PARIBAS, on June 30, 2020, the following resources appeared in the liquidity account.

21,716 THERANEXUS titles, 177,017.32 euros

It is recalled that during the implementation (on the date of entry into force of the contract in accordance with AMF decision n -degree 2018-01 of July 2, 2018 - position as of 12/31/2018), the following resources were included in liquidity account: 14,114 THERANEXUS titles, 95,788.55 euros During the 1 st half of 2020, he was traded a total of:

Purchases: 222,000 titles

EUR 1,310,366: 865 transactions

Sales: 235,252 titles

EUR 1,444,872: 829 transactions

ABOUT THERANEXUS

Founded in 2013, THERANEXUS is a clinical-stage biopharmaceutical company, from the CEA, which develops drug candidates for the treatment of diseases of the nervous system. THERANEXUS has identified the major role of non-neuronal cells (otherwise known as 'glial cells') in the response to psychotropic drugs (targeting neurons). The company is a pioneer in the design and development of drug candidates acting on the interaction between neurons and glial cells. The unique and patented technology exploited by THERANEXUS aims to increase the effectiveness of psychotropic drugs already approved and marketed by combining them with a glial cell modulator. This strategy of combining repositioned drugs enables it to significantly reduce development time and costs and considerably increase the chances of market access for its drugs.

Proprietary and adaptable, the THERANEXUS platform makes it possible to generate various proprietary drug candidates with high added value in several indications.

Contact:

Tel: 33 (0) 6 07 76 82 83

Email: fportejoie@fp2com.fr

(C) 2020 Electronic News Publishing, source ENP Newswire